Antigen-Specific Peptide Immunotherapy for Type 1 Diabetes: Proof of Safety, Hope for Efficacy.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 28978425.
- Also identified by DOI 10.1016/j.cmet.2017.09.016.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Antigen-specific immunotherapy has long been hailed as the ideal disease-modifying approach for type 1 diabetes, both for disease prevention and reversal. A small phase 1 trial now demonstrates safety of a peptide-based treatment in recently diagnosed adults.
Medical subject headings
- Diabetes Mellitus, Type 1
- Immunotherapy
- Proinsulin